-
England 'flat' as Crawley admits Australia a better side
-
Australia four wickets from Ashes glory as England cling on
-
Beetles block mining of Europe's biggest rare earths deposit
-
French culture boss accused of mass drinks spiking to humiliate women
-
NBA champions Thunder suffer rare loss to Timberwolves
-
Burning effigy, bamboo crafts at once-a-decade Hong Kong festival
-
Joshua knocks out Paul to win Netflix boxing bout
-
Dogged Hodge ton sees West Indies save follow-on against New Zealand
-
England dig in as they chase a record 435 to keep Ashes alive
-
Wembanyama 26-point bench cameo takes Spurs to Hawks win
-
Hodge edges towards century as West Indies 310-4, trail by 265
-
US Afghans in limbo after Washington soldier attack
-
England lose Duckett in chase of record 435 to keep Ashes alive
-
Australia all out for 349, set England 435 to win 3rd Ashes Test
-
US strikes over 70 IS targets in Syria after attack on troops
-
Australian lifeguards fall silent for Bondi Beach victims
-
Trump's name added to Kennedy Center facade, a day after change
-
West Indies 206-2, trail by 369, after Duffy's double strike
-
US strikes Islamic State group in Syria after deadly attack on troops
-
Epstein files opened: famous faces, many blacked-out pages
-
Ravens face 'special' Patriots clash as playoffs come into focus
-
Newly released Epstein files: what we know
-
Musk wins US court appeal of $56 bn Tesla pay package
-
US judge voids murder conviction in Jam Master Jay killing
-
Trump doesn't rule out war with Venezuela
-
Haller, Aouar out of AFCON, Zambia coach drama
-
Nasdaq rallies again while yen falls despite BOJ rate hike
-
Bologna win shoot-out with Inter to reach Italian Super Cup final
-
Brandt and Beier send Dortmund second in Bundesliga
-
Trump administration begins release of Epstein files
-
UN Security Council votes to extend DR Congo mission by one year
-
Family of Angels pitcher, club settle case over 2019 death
-
US university killer's mystery motive sought after suicide
-
Rubio says won't force deal on Ukraine as Europeans join Miami talks
-
Burkinabe teen behind viral French 'coup' video has no regrets
-
Brazil court rejects new Bolsonaro appeal against coup conviction
-
Three-time Grand Slam winner Wawrinka to retire in 2026
-
Man Utd can fight for Premier League title in next few years: Amorim
-
Pandya blitz powers India to T20 series win over South Africa
-
Misinformation complicated Brown University shooting probe: police
-
IMF approves $206 mn aid to Sri Lanka after Cyclone Ditwah
-
US halts green card lottery after MIT professor, Brown University killings
-
Stocks advance as markets cheer weak inflation
-
Emery says rising expectations driving red-hot Villa
-
Three killed in Taipei metro attacks, suspect dead
-
Seven Colombian soldiers killed in guerrilla attack: army
-
Amorim takes aim at Man Utd youth stars over 'entitlement'
-
Mercosur meets in Brazil, EU eyes January 12 trade deal
-
US Fed official says no urgency to cut rates, flags distorted data
-
Rome to charge visitors for access to Trevi Fountain
Avant Technologies and Partner, Ainnova, Receive FDA Pre-Submission Meeting Date for Company’s Vision AI Platform Technology
LAS VEGAS, NEVADA / ACCESS Newswire / May 6, 2025 / Avant Technologies Inc. (OTCQB:AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that the U.S. Food and Drug Administration (FDA) has scheduled its pre-submission meeting with Ainnova's executives and its CRO, Fortrea, for July 7, 2025, to discuss a range of items related to the Company's planned clinical trial of its Vision AI platform in the early detection of diabetic retinopathy.
Vinicio Vargas, Chief Executive Officer at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio, said, "We are forever grateful for the opportunity to meet with the U.S. FDA to discuss our planned clinical trial. These meetings will give us the direction that we'll need for success and to support our FDA 510(k) submission to obtain clearance from the FDA to market our technology in the U.S."
"We will use this pre-submission meeting to determine a host of items, including the ideal number of clinical sites, the number of total patients needed, and to learn if the FDA will approve our protocol for the planned clinical trial. These are all crucial for both Avant and Ainnova in determining the exact costs and a timetable."
AAC has the worldwide licensing rights for Ainnova's technology portfolio. The licensing rights include the U.S., where the FDA regulates drug and medical device development, so the success of Ainnova's interactions with the FDA are paramount to marketing the technology portfolio in the United States. Entering the U.S. market will unlock significant commercial potential, and this early engagement with the FDA ensures AAC can do so with speed, credibility, and a validated product.
About Ainnova Tech, Inc.
Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI - our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.
About Avant Technologies Inc.
Avant Technologies Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.
More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
https://twitter.com/AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Contact:
Avant Technologies Inc.
[email protected]
SOURCE: Avant Technologies
View the original press release on ACCESS Newswire
Th.Gonzalez--AT